ClinicalTrials.Veeva

Menu
R

Retina Foundation of the Southwest | Dallas, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

QR-421a
VP-001
Zimura
BI 754132
docosahexaenoic acid
RO7303359
ANX007
Valproic Acid
AGTC-501
BI 771716

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 68 total trials

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: 4D-125 IVT Injection
Other: Observational
Locations recently updated

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to a...

Enrolling
X-Linked Retinitis Pigmentosa
Drug: Control
Biological: rAAV2tYF-GRK1-hRPGRco

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO muta...

Enrolling
Retinitis Pigmentosa
Genetic: Sub-Retinal Administration of OCU400-301

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a...

Invitation-only
X-Linked Retinitis Pigmentosa
Biological: AGTC-501 (high dose and modified corticosteroid regimen)
Biological: AGTC-501 (high dose and standard corticosteroid regimen)

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retini...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: rAAV2tYF-GRK1-RPGR

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in sub...

Active, not recruiting
Eye Diseases, Hereditary
Vision Tunnel
Drug: QR-1123
Other: Sham procedure

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Begins enrollment this month
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated vi...

Active, not recruiting
Choroideremia
Biological: 4D-110

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants wit...

Not yet enrolling
Retinal Degeneration
Retinal Dystrophies
Drug: VP-001

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants...

Enrolling
PRPF31 Mutationassociated Retinal Dystrophy
Retinal Dystrophy
Drug: VP-001

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retini...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Biological: rAAV2tYF-GRK1-RPGR

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD)....

Enrolling
Geographic Atrophy
Genetic: OCU410

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.This is a multicenter study, which will be conducted in...

Enrolling
Stargardt Disease
Genetic: OCU410ST

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human cl...

Enrolling
Cone Rod Dystrophy
Stargardt Disease
Drug: ACDN-01

The purpose of this Phase 2b study is to evaluate the safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in subjects...

Enrolling
Eye Diseases, Hereditary
Eye Disorders Congenital
Other: No intervention, will not receive any active study intervention
Drug: Intravitreal Injection of Ultevursen

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with a...

Active, not recruiting
Stargardt's Macular Dystrophy
Drug: Sham
Drug: avacincaptad pegol

Trial sponsors

R
B
Thea Pharma logo
4
A
Genentech logo
Jaeb Center for Health Research logo
Ocugen logo
P
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems